Oramed Files To Raise $100M On Nasdaq

January 28, 2014 | Israeli company Oramed Pharmaceuticals, which is developing a revolutionary insulin pill for diabetics, has filed a request to raise $100 million on Nasdaq. The company is already publicly traded and has shown a rise in stock since its report of a successful trial for its type 1 diabetes treatment.